Archived News
2005
Ascenta AT-101 Data Presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, Georgia
Return to top of page
Ascenta AT-101 Clinical Trial Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania
Preclinical Data on Ascenta Therapeutics Pipeline Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania
Return to top of page
November 10, 2005
Phase II Program of Ascenta's Lead Product, AT-101, a Pan-inhibitor of the Bcl-2 Protein Family, Begins
Return to top of page
Mel Sorensen, MD of Ascenta Therapeutics, Speaks at the Moores Cancer Center Symposium
Return to top of page
September 21, 2005
Ascenta Therapeutics Opens an R&D Center in Shanghai's High-Tech Park in Pu-Dong, China
Return to top of page
Ascenta Therapeutics Moves to New Offices in San Diego, California
Return to top of page
Appointment of Three New Vice-Presidents to the Executive Team at Ascenta Therapeutics
Return to top of page
Ascenta Therapeutics Leaders Participate in Shanghai's Bio-Forum Conference
Return to top of page
April 18, 2005
Mel Sorensen, MD of Ascenta Therapeutics, Speaks at the Milken Institute's Global Conference in Los Angeles
Return to top of page
April 5, 2005
Mel Sorensen, MD, President and CEO of Ascenta Therapeutics, Speaks at Tokyo's Pharma Partnering Conference
Return to top of page
First Patient Entered onto Ascenta Therapeutics' Phase I Trial of its Lead Product, AT-101, a Pan-inhibitor of the Bcl-2 Protein Family
Return to top of page
